Clinical Study on the Intervention of Xuesaitong Soft Capsules in Post-Intervention Patients with Acute Coronary Syndrome and Clinical Research Protocol

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 400 participants.

Also called NCT06845254

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 400 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06845254
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT06845254. Randomized; double masking; primary purpose treatment. Start 2025-03-01 (anticipated); primary completion 2025-10-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Clinical Study on the Intervention of Xuesaitong Soft Capsules in Post-Intervention Patients with Acute Coronary Syndrome and Clinical Research Protocol
Condition
Acute Coronary Syndrome
Intervention (Drug)
Xuesaitong soft capsule (main ingredient is Panax notoginseng saponins)
Intervention (Drug)
placebo capsule
Lead sponsor
Xiyuan Hospital of China Academy of Chinese Medical Sciences (class: other)

Record details

Record id
cardio:ct-nct06845254
Content hash
e4c4e813fbdc3c2665bf5321f3db84a50730b49b3f90326568bdcacac3a11e58